NCT02658734COMPLETEDanonymous

A Multicenter, Open-Label, Single-Arm, Phase IV Study of Trastuzumab Emtansine in Indian Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

Sponsor

Source record

Hoffmann-La Roche

Phase

Source record

Phase IV

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Indication / condition

AI-normalized

HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

Intervention

Source record

Trastuzumab emtansine

Source & freshness

Source record

NCT ID

NCT02658734

Original source

ClinicalTrials.gov

Source last updated

Apr 02, 2021

Ingested at

Jun 05, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT02658734

Title

A Multicenter, Open-Label, Single-Arm, Phase IV Study of Trastuzumab Emtansine in Indian Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

Sponsor

Hoffmann-La Roche

Status

COMPLETED

Phase

Phase IV

Condition raw

HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

Condition normalized

HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Trastuzumab emtansine

Target normalized

HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Interventions

Trastuzumab emtansine

Public preview

Source record

This study evaluated the safety of trastuzumab emtansine in Indian patients with HER2-positive breast cancer who had prior treatment with trastuzumab and a taxane. Conducted by Hoffmann-La Roche, it involved 70 participants across 13 centers in India.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Multicenter, Open-Label, Single-Arm, Phase IV Study of Trastuzumab Emtansine in Indian Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02658734

Status

COMPLETED

Phase

Phase IV

Sponsor

Hoffmann-La Roche

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedApr 02, 2021

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02658734

Indication

HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

Modality

monoclonal antibody

Target

HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Intervention

Trastuzumab emtansine

Source record